These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36949264)

  • 21. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.
    Yarchoan M; Arnold SE
    Diabetes; 2014 Jul; 63(7):2253-61. PubMed ID: 24931035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.
    Pelle MC; Zaffina I; Giofrè F; Pujia R; Arturi F
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.
    Hierro-Bujalance C; Infante-Garcia C; Del Marco A; Herrera M; Carranza-Naval MJ; Suarez J; Alves-Martinez P; Lubian-Lopez S; Garcia-Alloza M
    Alzheimers Res Ther; 2020 Apr; 12(1):40. PubMed ID: 32264944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Alzheimer's disease a type 3 diabetes? A review.
    Janoutová J; Machaczka O; Zatloukalová A; Janout V
    Cent Eur J Public Health; 2022 Sep; 30(3):139-143. PubMed ID: 36239360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.
    Li X; Song D; Leng SX
    Clin Interv Aging; 2015; 10():549-60. PubMed ID: 25792818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease.
    Jojo GM; Kuppusamy G
    J Clin Pharm Ther; 2019 Jun; 44(3):337-348. PubMed ID: 30738020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus.
    Klimova B; Kuca K; Maresova P
    Curr Alzheimer Res; 2018; 15(14):1277-1282. PubMed ID: 30251605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Link Between Diabetes Mellitus and Tau Hyperphosphorylation: Implications for Risk of Alzheimer's Disease.
    Hobday AL; Parmar MS
    Cureus; 2021 Sep; 13(9):e18362. PubMed ID: 34725612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators.
    Jayaraj RL; Azimullah S; Beiram R
    Saudi J Biol Sci; 2020 Feb; 27(2):736-750. PubMed ID: 32210695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidiabetic therapies and Alzheimer disease.
    Bendlin BB
    Dialogues Clin Neurosci; 2019 Mar; 21(1):83-91. PubMed ID: 31607783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Action of Polyphenols in Diabetes Mellitus and Alzheimer's Disease: A Common Agent for Overlapping Pathologies.
    Silveira AC; Dias JP; Santos VM; Oliveira PF; Alves MG; Rato L; Silva BM
    Curr Neuropharmacol; 2019; 17(7):590-613. PubMed ID: 30081787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
    Shi L; Zhang Z; Li L; Hölscher C
    Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities.
    Bednarz K; Siuda J
    Neurol Neurochir Pol; 2021; 55(5):418-428. PubMed ID: 34355790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - A Register-based Study.
    Kullenberg H; Wibom M; Kumlin M; Nyström T; Svedberg MM
    Curr Alzheimer Res; 2023; 20(2):109-119. PubMed ID: 37221687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
    Tramutola A; Arena A; Cini C; Butterfield DA; Barone E
    Expert Rev Neurother; 2017 Jan; 17(1):59-75. PubMed ID: 27715341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of liraglutide in Alzheimer's disease pathology.
    Vargas-Soria M; Carranza-Naval MJ; Del Marco A; Garcia-Alloza M
    Alzheimers Res Ther; 2021 Jun; 13(1):112. PubMed ID: 34118986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies.
    Luo A; Ning P; Lu H; Huang H; Shen Q; Zhang D; Xu F; Yang L; Xu Y
    J Alzheimers Dis; 2022; 88(4):1311-1323. PubMed ID: 35786654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings.
    Khezri MR; Yousefi K; Mahboubi N; Hodaei D; Ghasemnejad-Berenji M
    Biochem Pharmacol; 2022 Mar; 197():114945. PubMed ID: 35134385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.